Published in:
01-12-2018 | ASO Author Reflections
ASO Author Reflections: Cytoreduction for Extrahepatic Metastatic Neuroendocrine Tumors
Authors:
David L. Chan, MBBS, Julie Hallet, MD, MSc
Published in:
Annals of Surgical Oncology
|
Special Issue 3/2018
Login to get access
Excerpt
Neuroendocrine tumors (NETs) are heterogeneous. Patients with low-grade tumors may experience disease stability for many years because of its indolent biology, but experience chronic systemic symptoms from hormonal secretion. Debulking of metastatic disease may therefore be appropriate to reduce tumor burden and hormonal load. Several studies attest to the safety of cytoreductive surgery in patients with liver-limited metastases;
1,
2 however, there are few data regarding cytoreduction in patients with extrahepatic metastases, and even fewer in the era of long-acting somatostatin analogs (LA-SSAs). This study sought to define the outcomes of surgical cytoreduction in patients with low-grade NETs and extrahepatic metastases. …
